Hematological Malignancies

Hematological Malignancies

Global Hematological Malignancies Market to Reach $71.6 Billion by 2030
The global market for Hematological Malignancies estimated at US$46.8 Billion in the year 2023, is expected to reach US$71.6 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2023-2030. Leukemia, one of the segments analyzed in the report, is expected to record a 7% CAGR and reach US$30.3 Billion by the end of the analysis period. Growth in the Lymphoma segment is estimated at 6.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $14.1 Billion, While China is Forecast to Grow at 5.7% CAGR
The Hematological Malignancies market in the U.S. is estimated at US$14.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.3 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 5.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 44 Featured) -
  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Hematological Malignancies - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Hematological Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Hematological Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Hematological Malignancies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Other Disease Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Other Disease Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Other Disease Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 25: World Hematological Malignancies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
JAPAN
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
CHINA
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
EUROPE
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Hematological Malignancies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Hematological Malignancies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Hematological Malignancies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
FRANCE
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
GERMANY
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
UNITED KINGDOM
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Rest of Europe Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Rest of Europe 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Europe Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Europe 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Hematological Malignancies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Asia-Pacific Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Asia-Pacific 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Asia-Pacific Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Asia-Pacific 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 95: Rest of World Recent Past, Current & Future Analysis for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of World Historic Review for Hematological Malignancies by Disease Condition - Leukemia, Lymphoma, Myeloma and Other Disease Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of World 16-Year Perspective for Hematological Malignancies by Disease Condition - Percentage Breakdown of Value Sales for Leukemia, Lymphoma, Myeloma and Other Disease Conditions for the Years 2014, 2024 & 2030
TABLE 98: Rest of World Recent Past, Current & Future Analysis for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of World Historic Review for Hematological Malignancies by Therapy - Chemotherapy, Immunotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of World 16-Year Perspective for Hematological Malignancies by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy and Targeted Therapy for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings